CCL2 and prostate carcinoma: Inhibition of CCL2 depletes inflammatory monocytes and macrophages, reducing tumor growth and dissemination in different experimental models, such as prostate cancer, melanoma, breast cancer, lung cancer, and liver cancer [28].